EESTECH Inc - Release From SEC Filing
LOS ANGELES, Feb. 18 /PRNewswire-FirstCall/ -- The Board of Directors wishes to confirm to Stockholders that at its meeting on February 4, 2009 it resolved to file a Form 15 with effect from February 17, 2009. This initiative does not require the approval of stockholders but in the interests of k...Former Telomolecular CEO Clarifies SEC Settlement
Former Telomolecular CEO, Matthew Sarad, clarifies the scope and terms of his settlement with the SEC. Case No. 2:08-cv-2252-GEB-DAD. (PRWEB) November 3, 2008 -- Telomolecular, a Rancho Cordova, California Corporation, was formed in 2005 to develop and license new nanot...Coherent, Inc. Announces Termination of SEC Informal Inquiry
SANTA CLARA, Calif., July 10 /PRNewswire-FirstCall/ -- Coherent, Inc. (Nasdaq: COHR ), today announced that the Securities and Exchange Commission has formally notified the Company that its investigation of Coherent's historical stock option granting practices has been terminated and that it ...Immucor Settles SEC Investigation
Court Approves Class Action Settlement NORCROSS, Ga., Sept. 28 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD ), the global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that the Securities and Exchange Comm...Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
WALTHAM, Mass., Aug. 20 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO ) announced today that certain executive officers, including Marijn E. Dekkers, president and chief executive officer, are adopting stock- trading programs under Securities and Exchange Commission (SEC)...Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
AURORA, Ontario, March 12 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") announced that its registration statement on Form 20-F has been declared effective by the U.S. Securities and Exchange Commission ("SEC"). Accordingly, Helix's common shares are now registered with the SEC pursu...NeoGenomics Files Annual Report on Form 10-KSB with the SEC
Also Announces Change to Unaudited Financial Results Released March 18, 2008 FT. MYERS, Fla., April 15 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) announced today that it had filed with the Securities and Exchange Commission its annua...VaxGen Files Last Outstanding Periodic Report With SEC
Plans to Initiate Process to Re-list Common Shares SOUTH SAN FRANCISCO, Calif., Oct. 4 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN) announced today that it has filed its Form 10-Q for the quarter ended June 30, 2007, thereby bringing the company current on its financia...Star panel re-evaluates Sarbanes-Oxley one year in at SEC headquarters
Washington, D.C. A full house packed the Securities and Exchange Commission headquarters on Wednesday for a public forum to discuss the most onerous section of The Sarbanes-Oxley Act of 2002 (or Sarbanes-Oxley), Section 404. The event was a roundtable of public companies, auditors, investor...KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid
... Matters" in the Company's Form 8-K filed with the sec on April 30, 2009; (16) the possibility that the C...er ended June 30, 2008, Form 12b-25 filed with the sec on November 13, 2008, Form 12b-25 filed with the sec on February 2, 2009, Form 12b-25 filed with the...Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product
...ition from other technologies. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's sec filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company unde...Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
...pany has filed with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the sec are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any...InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
...ut are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the sec on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions ...China Sky One Medical, Inc. Appoints New Independent Director
...e Audit Committee, Compensation Committee and Finance Committee of the Board of Directors, and as "audit committee financial expert" as defined by the sec rules adopted pursuant to the Sarbanes-Oxley Act of 2002. Mr. Wei Lee has over 15 years of experience in financial services and government rela...Micromet Closes $80.5 Million Public Offering of Common Stock
...se factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the sec on May 11, 2009, as well as other filings by the company with the SEC. ...SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS
...ery and development collaborations on current terms. These and other risks and uncertainties are described more fully in Senomyx's most recently filed sec documents, including its Annual Report on Form 10-K and its most recent quarterly report on Form 10-Q under the headings "Risks Related to Our Busines...Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
...in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the sec and/or Canadian regulatory authorities. Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can gi...Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
...in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the sec and/or Canadian regulatory authorities. Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can gi...CuraGen Reports Second Quarter 2009 Financial Results
...liminary joint proxy statement/prospectus with the sec on June 26, 2009. This joint proxy statement/prosp...her documents filed by Celldex or CuraGen with the sec may be obtained free of charge at the SEC's websit...obtain free copies of the documents filed with the sec (i) by contacting CuraGen Corporation, Attn: VP &a...TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction
...tus and Raptor's and TorreyPines' filings with the sec can also be obtained, without charge, by directing...ormation filed by Raptor and/or TorreyPines at the sec public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the sec at 1-800-SEC-0330 for further information on the p...Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
...lity to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' sec filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Current Report on Form 8-K filed on June 4, 2009. All forward-l...Micromet Announces Pricing of Public Offering of Common Stock
...se factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the sec on May 11, 2009, as well as other filings by the company with the SEC. ...Cornerstone Therapeutics Announces Closing of Chiesi Transaction
...connection with the transaction with Chiesi, Cornerstone has filed with the sec a preliminary proxy statement and other documents regarding proposed amendm...tatement (when available) and other documents filed by Cornerstone with the sec at the SEC's website at www.sec.gov or from Cornerstone's website at ...Cardiogenesis Corporation Makes Pre-IDE Submission for PHOENIX Combination Delivery System
...iscussed in the "Risk Factors" section of the company's Annual Report on Form 10-K for the year ended December 31, 2008 and the company's other recent sec filings. The company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this pr...Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009
...any or by persons acting on its behalf and in conjunction with its periodic sec filings. In addition, please refer to the cautionary statements and risk fa...te that its Form 10-Q for the quarter ended June 30, 2009 is filed with the sec could potentially result in adjustments to reported results. The company un...Micromet Announces Public Offering of Common Stock
...se factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the sec on May 11, 2009, as well as other filings by the company with the SEC. ...Sanofi-aventis Announces Second Quarter 2009 Results
...lternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the sec and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in san...BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
...erformances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the sec and located at www.shareholder.com/biocryst/edgar.cfm . BCRXW ...